RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer (NSCLC). This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback